Valneva SE (VALN) Income towards Parent Company (2021 - 2026)
Valneva SE (VALN) posted quarterly Income towards Parent Company of -$27.0 million for Q1 2026, down 297.58% year-on-year from $13.6 million in Q1 2025, and up 52.68% on a QoQ basis from -$57.0 million in Q4 2025.
Valneva SE (VALN) Income towards Parent Company (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Income towards Parent Company for 6 consecutive years, with -$27.0 million the latest figure, recorded in Q1 2026.
- Quarterly Income towards Parent Company fell 297.58% year-over-year to -$27.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$151.4 million (down 118.64% YoY) and the FY2025 annual result came in at -$131.1 million, down 964.36% from the prior year.
- Income towards Parent Company grew to -$27.0 million in Q1 2026 per VALN's latest filing, from -$57.0 million in the prior quarter.
- Over the last five years, Income towards Parent Company for VALN reached as high as $106.2 million in Q3 2022 and fell as low as -$161.5 million in Q2 2022.
- A 5-year average of -$22.6 million and a median of -$25.0 million in 2024 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2024 — Income towards Parent Company surged 511.54% — and 2025, when it tumbled 340.45%.
- Year by year, Income towards Parent Company stood at -$64.1 million in 2022, then jumped by 55.8% to -$28.3 million in 2023, then surged by 54.35% to -$12.9 million in 2024, then slumped by 340.45% to -$57.0 million in 2025, then soared by 52.68% to -$27.0 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$27.0 million, -$57.0 million, and -$55.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Valneva SE | 839.21 Mn | 719.43 Mn | 5.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.96 Mn |
| Dec 31, 2025 | -56.99 Mn |
| Sep 30, 2025 | -55.04 Mn |
| Jun 30, 2025 | -12.37 Mn |
| Mar 31, 2025 | -6.78 Mn |
| Dec 31, 2024 | -12.94 Mn |
| Sep 30, 2024 | -24.99 Mn |
| Jun 30, 2024 | -24.52 Mn |
| Mar 31, 2024 | 77.62 Mn |
| Dec 31, 2023 | -28.34 Mn |
| Sep 30, 2023 | -25.28 Mn |
| Jun 30, 2023 | -20.93 Mn |
| Mar 31, 2023 | -18.86 Mn |
| Dec 31, 2022 | -64.12 Mn |
| Sep 30, 2022 | 106.19 Mn |
| Jun 30, 2022 | -161.49 Mn |
| Mar 31, 2022 | -28.49 Mn |
| Dec 31, 2021 | 192.56 Mn |
| Sep 30, 2021 | -179.32 Mn |
| Jun 30, 2021 | -64.44 Mn |